Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.8
Journals
Current Oncology
Special Issues
2nd Edition: Treatment of Bone Metastasis
share announcement

2nd Edition: Treatment of Bone Metastasis

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Bone and Soft Tissue Oncology".

Deadline for manuscript submissions: 20 November 2024 | Viewed by 831

Special Issue Editor

Dr. Costantino Errani

E-Mail Website
Guest Editor
III Clinica di Ortopedia e Traumatologia, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy
Interests: bone tumors; soft tissue tumors; bone sarcomas; soft tissue sarcomas; bone metastases; limb salvage surgery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This collection is the second edition of a previous Special Issue, entitled "Treatment of Bone Metastasis”(https://www.mdpi.com/journal/curroncol/special_issues/Treatment_Bone_Metastasis).

The incidence of metastatic bone disease is increasing, as patients with cancer are living longer. Bone is the third most common site of metastatic disease, after the lungs and the liver. Long bone metastases are a common presentation in patients with advanced cancer, occurring in up to 70% of patients. In 2008, it was estimated that almost 300,000 patients with advanced cancer in the USA had skeletal metastases. Skeletal metastases can dramatically decrease patients’ quality of life as a result of skeletal related events. In 2006, the financial burden of treating patients with metastatic bone disease in the USA per year was estimated to be approximately 12.6 billion dollars, which accounted for 17% of the total annual cost of cancer treatments. Patients with metastatic bone disease may seek medical care at community hospitals. Traditional management techniques involve a combination of pharmacotherapy, radiotherapy, and surgical procedures. Over the last few decades, advances in medical and surgical treatments have been proposed regarding the management of metastatic bone disease. Considering the limited expectancy of most patients with bone metastases, the main goal of novel medical and less invasive treatments is to improve the quality of life of patients with bone metastases, reducing the adverse effects related to the traditional medical or surgical treatments.

We are pleased to invite the submission of manuscripts focusing on new research on basic, clinical, and surgical research on the treatment of bone metastases.

This Special Issue aims to explore all areas of treatment of bone metastases, including the following:

  • Surveillance imaging and diagnostic work to ensure the accurate and timely identification of bone metastases.
  • Current systemic treatment options with zolendronic acid and denosumab in order to provide knowledge of innovative techniques in evolving therapies.
  • The role of interventional radiology: embolization, electro-chemotherapy, magnetic resonance imaging guided high-intensity focused ultrasound, and thermal ablation therapies.
  • The search for possible prognostic factors affecting survival—the life expectancy of patients with bone metastases seems to be the most important factor in determining the surgical treatment, and in avoiding over- or under-treatments.
  • The role of surgery: based on the risk of surgical complications, the patient’s prognosis seems to be important regarding the type of surgical treatment in a patient with bone metastases.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: nuclear medicine, radiology, interventional radiology, orthopedics, and oncology.

We look forward to receiving your contributions.

Dr. Costantino Errani
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bone metastases
  • imaging
  • prognostic factors
  • prognostic score
  • novel therapies
  • medical treatments
  • interventional radiology
  • surgery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

10 pages, 2487 KiB  
Article
Augmented Reality Navigation System (SIRIO) for Neuroprotecion in Vertebral Tumoral Ablation
by Eliodoro Faiella, Rebecca Casati, Matteo Pileri, Giuseppina Pacella, Carlo Altomare, Elva Vergantino, Amalia Bruno, Bruno Beomonte Zobel and Rosario Francesco Grasso
Curr. Oncol. 2024, 31(9), 5088-5097; https://doi.org/10.3390/curroncol31090376 - 30 Aug 2024
Viewed by 427
Abstract
(1) This study evaluates the impact of the CT-guided SIRIO augmented reality navigation system on the procedural efficacy and clinical outcomes of neuroprotection in vertebral thermal ablation (RTA) for primary and metastatic bone tumors. (2) Methods: A retrospective non-randomized analysis of 28 vertebral [...] Read more.
(1) This study evaluates the impact of the CT-guided SIRIO augmented reality navigation system on the procedural efficacy and clinical outcomes of neuroprotection in vertebral thermal ablation (RTA) for primary and metastatic bone tumors. (2) Methods: A retrospective non-randomized analysis of 28 vertebral RTA procedures was conducted, comparing 12 SIRIO-assisted and 16 non-SIRIO-assisted procedures. The primary outcomes included dose-length product (DLP) and epidural dissection time. The secondary outcomes included technical success, complication rates, and pain scores at procedural time (VAS Time 0) and three months post-procedure (VAS Time 1). The statistical analyses included t-tests, Mann–Whitney U tests, and multiple regression. (3) Results: SIRIO-assisted procedures significantly reduced DLP (307.42 mGycm vs. 460.31 mGycm, p = 2.23 × 10−8) and procedural epidural dissection time (13.48 min vs. 32.26 min, p = 2.61 × 10−12) compared to non-SIRIO-assisted procedures. Multiple regression confirmed these reductions were significant (DLP: β = −162.38, p < 0.001; time: β = −18.25, p < 0.001). Pain scores (VAS Time 1) did not differ significantly between groups, and tumor type did not significantly influence outcomes. (4) Conclusions: The SIRIO system enhances neuroprotection efficacy and safety, reducing radiation dose and procedural time during spine tumoral ablation while maintaining consistent pain management outcomes. Full article
(This article belongs to the Special Issue 2nd Edition: Treatment of Bone Metastasis)
►▼ Show Figures

Figure 1

Other

Jump to: Research

17 pages, 707 KiB  
Systematic Review
Exploring the Efficacy of Combining Radiofrequency Thermal Ablation or Microwave Ablation with Vertebroplasty for Pain Control and Disease Management in Metastatic Bone Disease—A Systematic Review
by Eliodoro Faiella, Federica Vaccarino, Giuseppina Pacella, Domiziana Santucci, Elva Vergantino, Amalia Bruno, Raffaele Ragone, Bruno Beomonte Zobel and Rosario Francesco Grasso
Curr. Oncol. 2024, 31(9), 5422-5438; https://doi.org/10.3390/curroncol31090401 (registering DOI) - 13 Sep 2024
Abstract
Background: Interventional radiology techniques have become pivotal in recent years in managing metastatic bone disease, which frequently results in skeletal complications such as fractures and severe pain. Thermoablative methods like radiofrequency ablation (RFA) and microwave ablation (MWA), when combined with vertebroplasty (VP), are [...] Read more.
Background: Interventional radiology techniques have become pivotal in recent years in managing metastatic bone disease, which frequently results in skeletal complications such as fractures and severe pain. Thermoablative methods like radiofrequency ablation (RFA) and microwave ablation (MWA), when combined with vertebroplasty (VP), are proving increasingly beneficial for these patients. Methods: The search was independently conducted by two radiologists on MEDLINE databases, using specified strings up to April 2024. Methodological quality was assessed using PRISMA guidelines. Studies meeting inclusion criteria investigated thermoablation techniques (RFA and/or MWA) combined with VP, focusing on pain management and disease control outcomes in adults. Results: Among 147 results, 42 articles met the criteria, with varied prospective and retrospective designs and sample sizes averaging 49 patients, predominantly involving RFA (30 studies), MWA (11 studies), and one comparative study. Our review highlights significant pain reduction, effective local tumor control, and favorable safety of combined RFA or MWA with VP, supporting its potential in managing vertebral pathologies and warranting further clinical integration. Conclusions: The combined treatment of RFA/MWA with VP demonstrates significant pain reduction and local tumor control, with a rapid onset of analgesic effect. These findings support its crucial role in clinical practice for managing vertebral metastases. Full article
(This article belongs to the Special Issue 2nd Edition: Treatment of Bone Metastasis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop